Novel Therapies for Respiratory Diseases
Kither Biotech
Kither Biotech is a clinical-stage biotech company dedicated to developing innovative cell signal transduction modulators delivered directly to the lung for the treatment of several respiratory diseases.
Kither is currently focusing its R&D efforts on Chronic Obstructive Pulmonary Disease (COPD), while planning to expand into further respiratory indications such as Non-Cystic Fibrosis Bronchiectasis (NCFBE), Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF).
The company’s lead asset, KIT2014, is a novel inhaled peptide designed to modulate intracellular cAMP signaling through balanced PDE3/4 inhibition. A Phase 1 clinical trial was successfully completed in healthy volunteers in 2025, and Kither is now initiating a Phase 2 clinical study in patients with COPD.
Kither’s pipeline also includes KITCL27, a small-molecule PI3K inhibitor prodrug in development for the treatment of IPF.
Science
(Breve testo), tincidunt non, euismod vitae, posuere imperdiet, leo. Nunc nonummy metus. Integer tincidunt. Vivamus euismod mauris. Pellentesque egestas, neque sit amet convallis pulvinar,
Drug development
Kither Biotech is a clinical-stage biotech company developing novel inhaled therapies targeting the PI3Kγ signaling axis for the treatment of respiratory diseases with high unmet medical need, including COPD, NCFBE, IPF, and CF.